Emerald Health Biotechnology is a preclinical stage drug development company focused on new cannabinoid derivatives for the treatment of serious life-threatening conditions and other pathologies. The Company is worldwide pioneer in the development of cannabidiol and cannabigerol chemical derivatives that improve the therapeutic properties of the natural compounds.

The current pipeline of the company is:

EHB R&D program are in continuous growth with the assessment of new molecules and new indications. To support the advancement of our candidates, EHB has assembled a proven management and scientific team with expertise in drug discovery and preclinical development. In addition, we have established a strong patent portfolio protecting the IP of our novel candidates.
EHB vision is to be worldwide leaders in the development of new molecules acting on the endocannabinoid system, targeting unmet clinical needs in chronic inflammatory diseases. EHB was founded in 2003, under the name VivaCell Biotechnology España, as a spin-off of the AINP (FP-V) and Cannabis (FP-VI) EU projects by a group of internationally renowned researchers in biomedicine, pharmacology and chemistry of natural products.

EHB is based at the Technological & Scientific Park of Córdoba (Spain). The facilities include head office and R&D laboratories which are equipped with the best technology for biomedicine research.
In house R&D is complemented with partnerships with top-class Research Centers such as IMIBIC (University of Córdoba), CIBERNED and IRYCIS (University Complutense of Madrid), CSIC - (Madrid), and University of Piemonte Orientale (Italy).
This flexible model allows us to allocate the most appropriate resources to each project, optimizing the know-how, and offering a wide range of capabilities to the company to perform different types of projects.